2 September 2010, 5:16 am
TUSTIN, CA--(Marketwire - September 2, 2010) - Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter fiscal year 2011 on September 9, 2010 after market and will host a conference call ...... Read More »